Innovent Biologics Inc IVBXF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $4.92
- Day Range
- $4.91–4.91
- 52-Week Range
- $3.55–6.41
- Bid/Ask
- $3.79 / $5.69
- Market Cap
- $7.96 Bil
- Volume/Avg
- 400 / 3,986
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.73
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 4,872
- Website
- https://www.innoventbio.com
Competitors
Valuation
|
Metric
|
IVBXF
|
01099
|
02269
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 6.46 | 14.89 |
Price/Book Value | 5.08 | 0.75 | 1.41 |
Price/Sales | 8.73 | 0.09 | 3.17 |
Price/Cash Flow | — | 3.14 | 10.10 |
Price/Earnings
IVBXF
01099
02269
Financial Strength
|
Metric
|
IVBXF
|
01099
|
02269
|
|---|---|---|---|
Quick Ratio | 2.59 | 1.05 | 2.35 |
Current Ratio | 3.00 | 1.39 | 2.78 |
Interest Coverage | −15.20 | 7.35 | 25.95 |
Quick Ratio
IVBXF
01099
02269
Profitability
|
Metric
|
IVBXF
|
01099
|
02269
|
|---|---|---|---|
Return on Assets (Normalized) | −2.13% | 4.43% | 8.91% |
Return on Equity (Normalized) | −3.97% | 24.34% | 13.28% |
Return on Invested Capital (Normalized) | −4.85% | 9.74% | 10.45% |
Return on Assets
IVBXF
01099
02269
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zcdzfghkld | Szj | $572.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ljjrjlg | Gxsdxv | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mjmsmgpfd | Qvfbvgl | $99.6 Bil | |
MRNA
| Moderna Inc | Pmhrpsgp | Bqyc | $42.7 Bil | |
ARGX
| argenx SE ADR | Mzzwlsk | Yrzx | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Rqqccgjv | Bsw | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zmpvcppr | Cnhcyw | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tcrdppywg | Ghrnz | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mbwtdtvsgd | Rwdhsk | $12.7 Bil | |
INCY
| Incyte Corp | Yjkgchx | Jhsjyq | $11.9 Bil |